Retevmo (selpercatinib) — Medica
Thyroid cancer, RET fusion-positive, RET mutation-positive, or RET pathogenic variant
Initial criteria
- Patient is age ≥ 2 years
- Patient has rearranged during transfection (RET) fusion-positive, RET mutation-positive disease, or RET pathogenic variant
- Patient meets ONE of the following: (i) Patient has anaplastic thyroid cancer; OR (ii) Disease requires systemic therapy AND patient meets ONE of the following: (a) Patient has medullary thyroid cancer; OR (b) Disease is radioactive iodine-refractory
Approval duration
1 year